Alisa Goldstein

Title: Alisa Goldstein: Innovator in Cancer Genetics

Introduction

Alisa Goldstein is a prominent inventor based in Rockville, MD (US). She has made significant contributions to the field of cancer genetics, particularly in understanding genetic predispositions to cancer. Her innovative work has implications for early diagnosis and treatment strategies.

Latest Patents

Goldstein holds a patent titled "Methods for the diagnosis of a genetic predisposition to cancer." This patent focuses on protein complexes consisting of a cyclin-dependent kinase CDK4 and cyclin D, which control the passage through the G1 checkpoint of the cell cycle by phosphorylating the retinoblastoma protein. The ability of these complexes to phosphorylate RB is inhibited by a family of low molecular weight proteins, including p16, p15, and p18. Germline mutations in the p16 gene have been identified in approximately half of families with hereditary melanoma. A specific mutation in CDK4, known as R24C, has been detected in melanoma patients, indicating its role as a dominant oncogene resistant to normal physiological inhibition by p16.

Career Highlights

Throughout her career, Goldstein has worked with notable organizations, including Sequana Therapeutics, Inc. and the United States of America. Her research has been pivotal in advancing the understanding of genetic factors in cancer.

Collaborations

Goldstein has collaborated with esteemed colleagues such as Nicolas Dracopoli and Margaret Tucker. These partnerships have further enriched her research and contributions to the field.

Conclusion

Alisa Goldstein's innovative work in cancer genetics exemplifies the impact of research on understanding genetic predispositions to cancer. Her contributions continue to influence the field and pave the way for future advancements in cancer diagnosis and treatment.